title: Using economics to assess the place of screening.
abstract: To an economist the place of screening is, in principle, no different from that of any other medical intervention. Any screening activity should be evaluated in terms of the costs it incurs and the benefits it produces. The reasoning for this is based on one fundamental principle of economics: that of opportunity cost. Resources are scarce, requiring choices to be made about what health care to provide and what not to provide. Sacrifices will be made through not taking up some opportunities, and the benefits of these sacrifices are known as opportunity costs. The place of economics is to assist decision making to promote efficiency and equity in the health care sector. To do this it is necessary to relate the benefits of any screening activity to its costs. Of course, the practicalities of applying economics to assessment of screening activities may be different than for other areas of health care. For instance, screening has a broader range of outcomes than most types of health care, including investment in knowledge as well as health gain. This does have implications for the way in which these outcomes are valued in an economic analysis. This means that economics can be applied to a wide range of policy questions about screening. In this paper examples from applications of economics are used to consider the following issues: How should we set out and estimate costs and benefits (using the example of cholesterol screening)? What is benefit and how should it be measured (using an example from cystic fibrosis carrier screening)? How can economics be used to examine equity issues in screening (using an example from bone mineral density screening)? Together, these case studies highlight the range of screening issues to which economics can be usefully applied.
authors.affiliation: Health Economics Research Unit, University of Aberdeen, United Kingdom.
authors.forename: C
authors.initials: C
authors.lastname: Donaldson
mesh_terms: D000328:Adult; D002784:Cholesterol / Q000097:blood; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D003550:Cystic Fibrosis / Q000517:prevention & control; D004813:Epidemiology; D006801:Humans; D006937:Hypercholesterolemia / Q000517:prevention & control; D008017:Life Expectancy; D008297:Male; D008403:Mass Screening / Q000191:economics*; D008875:Middle Aged
chemical_list: D002784:Cholesterol